Hoping for a Springboard

Biotech plodded through a mostly flat first quarter but surged in the last couple of weeks, giving biotech buysiders hope that a few better-than-expected product launches plus a slew of regulatory and clinical milestones in the next three months could return some of the momentum the sector saw late last year.

Bankers are hoping more stable financial markets could encourage more of the strong biotech financing activity seen at the end of 2010 and early 2011...